Amylyx Pharmaceuticals, Inc. 10-Q filing
Filed 2025-11-06 · Report date 2025-09-30 · 2025
Filing metadata
- Accession number
- 0001193125-25-268059
- Form type
- 10-Q
- CIK
- 0001658551
- Primary document
- https://www.sec.gov/Archives/edgar/data/1658551/000119312525268059/amlx-20250930.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Amylyx Pharmaceuticals, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $0 | - | - |
| Cost Of Revenue | $0 | - | - |
| Operating Income | $-116.7M | - | - |
| Net Income | $-111.7M | - | - |
| Eps Basic | -1.25 | - | - |
| Eps Diluted | -1.25 | - | - |
| Cash And Equivalents | $225.2M | - | - |
| Total Assets | $362.7M | - | - |
| Total Liabilities | $30.7M | - | - |
| Shareholders Equity | $332.0M | - | - |
| Operating Cash Flow | $-95.4M | - | - |
| Capital Expenditures | $52,000 | - | - |